Gilteritinib as Posttransplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3
J. Clin. Oncol 2024 Mar 12;[EPub Ahead of Print], MJ Levis, M Hamadani, B Logan, RJ Jones, AK Singh, M Litzow, JR Wingard, EB Papadopoulos, AE Perl, RJ Soiffer, C Ustun, M Ueda Oshima, GL Uy, EK Waller, S Vasu, M Solh, A Mishra, L Muffly, HJ Kim, JH Mikesch, Y Najima, M Onozawa, K Thomson, A Nagler, AH Wei, G Marcucci, NL Geller, N Hasabou, D Delgado, M Rosales, J Hill, SC Gill, R Nuthethi, D King, H Wittsack, A Mendizabal, SM Devine, MM Horowitz, YB ChenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.